Oppenheimer & Co
ALLO icon

Oppenheimer & Co’s Allogene Therapeutics ALLO Stock Holding History

Oppenheimer & Co’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.4K Hold
11,500
– – ﹤0.01% 1745
2026
Q2 		$23.9K Buy
11,500
+1,000
+10% +$2.2K ﹤0.01% 1751
2026
Q1 		$25.6K Buy
+10,500
New +$21K ﹤0.01% 1676
2025
Q4 		– Sell
-10,500
Closed -$13K – 1551
2025
Q3 		$13K Hold
10,500
– – ﹤0.01% 1644
2025
Q2 		$11.9K Hold
10,500
– – ﹤0.01% 1600
2025
Q1 		$15.3K Hold
10,500
– – ﹤0.01% 1558
2024
Q4 		$22.4K Hold
10,500
– – ﹤0.01% 1538
2024
Q3 		$29.4K Hold
10,500
– – ﹤0.01% 1493
2024
Q2 		$24.5K Hold
10,500
– – ﹤0.01% 1416
2024
Q1 		$46.9K Sell
10,500
-1,900
-15% -$7.93K ﹤0.01% 1410
2023
Q4 		$39.8K Hold
12,400
– – ﹤0.01% 1356
2023
Q3 		$39.3K Hold
12,400
– – ﹤0.01% 1350
2023
Q2 		$61.6K Buy
+12,400
New +$67.1K ﹤0.01% 1373
2022
Q4 		– Sell
-11,350
Closed -$123K – 1350
2022
Q3 		$123K Sell
11,350
-5,200
-31% -$70.7K ﹤0.01% 1281
2022
Q2 		$189K Buy
16,550
+1,500
+10% +$13.3K ﹤0.01% 1281
2022
Q1 		$137K Buy
15,050
+3,000
+25% +$31.2K ﹤0.01% 1399
2021
Q4 		$180K Sell
12,050
-1,095
-8% -$19.3K ﹤0.01% 1406
2021
Q3 		$338K Sell
13,145
-1,739
-12% -$41.3K 0.01% 1176
2021
Q2 		$388K Sell
14,884
-10,139
-41% -$289K 0.01% 1130
2021
Q1 		$883K Buy
+25,023
New +$844K 0.02% 749
2020
Q2 		– Sell
-13,300
Closed -$259K – 1257
2020
Q1 		$259K Buy
13,300
+5,500
+71% +$131K 0.01% 949
2019
Q4 		$203K Sell
7,800
-10,900
-58% -$300K 0.01% 1174
2019
Q3 		$510K Buy
18,700
+8,500
+83% +$242K 0.01% 786
2019
Q2 		$274K Buy
+10,200
New +$284K 0.01% 1038

Other funds holding ALLO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Oppenheimer & Co's ALLO Position: Q3 2026 in Review

Oppenheimer & Co held its Allogene Therapeutics (ALLO) position steady in Q3 2026 at 11,500 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Oppenheimer & Co first reported a position in ALLO in Q2 2019 and has held it in 24 quarters since. The position peaked at $883K in Q1 2021. 141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Oppenheimer & Co held 11,500 shares of Allogene Therapeutics worth $18.4K as of Q3 2026.
  • Oppenheimer & Co left its Allogene Therapeutics share count unchanged in Q3 2026.
  • Allogene Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1745 holding.
  • Oppenheimer & Co first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • Oppenheimer & Co's Allogene Therapeutics position peaked at $883K in Q1 2021.
  • 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.